LONDON – AstraZeneca PLC (AZN.LN) Thursday said the U.S. Food and Drug Administration has put some of its blood cancer treatment trials on hold after identifying risks in other drug trials that also use an anti-PD-L1 agent.
Continue Reading Below
Shares at 1146 GMT, up 47.5pence, or 1%, at 4624 pence valuing the company at GBP58.1 billion.
-Write to Rory Gallivan at firstname.lastname@example.org; Twitter: @RoryGallivan
(END) Dow Jones Newswires
September 07, 2017 08:03 ET (12:03 GMT)